第二代表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的研究进展
作者：唐亚娟;丁振宇;
Author：
收稿日期： 年卷（期）页码：2008,(05):-588-589
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：表皮生长因子受体;非小细胞肺癌;酪氨酸激酶抑制剂
Key words：
基金项目：
中文摘要
在非小细胞肺癌的分子靶向治疗中,表皮生长因子受体是有前景的治疗靶标。吉非替尼、尔洛替尼虽已批准上市用于临床,但其治疗的临床受益率较低。现对正在研发的第二代表皮生长因子受体酪氨酸激酶抑制剂的临床试验作一综述。
参考文献
[1]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional ran-domized phase II trial of gefitinib for previously treated patientswith advanced nonsmall-cell lung cancer(The IDEAL1 Trial)[J].J Clin Oncol,2003,21(12):2237-2246.
[2]Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,aninhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:Aran-domized trial[J].JAMA,2003,290(16):2149-2158.
[3]Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in theepidermal growth factor receptor underlying responsiveness ofnon-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
[4]Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung canc-er:Correlation with clinical response to gefitinib therapy[J].Sci-ence,2004,304(5676):1497-1500.
[5]Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutationsare common in lung cancers from“never smokers”and are asso-ciated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101(36):13306-13311.
[6]温华,张贺龙,康健.选择性表皮生长因子受体酪氨酸激酶抑制剂ZD1839对NK和LAK细胞毒作用的影响[J].中国免疫学杂志,2004,20(10):677-678.
[7]Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation andresistance of non-small-cell lung cancer to gefitinib[J].NEn-gl J Med,2005,352(20):786-792.
[8]Pao W,Miller VA,Politi KA,et al.Acquired resistance of lungadenocarcinomas to gefitinib or erlotinib is associated with a sec-ond mutation in the EGFR kinase domain[J].Plos Med,2005,2(9):e73.
[9]Yarden Y,Sliwkowski MX.Untangling the ErbB signalling net-work[J].Nat Rev Mol Cell Biol,2001,2(2):127-137.
[10]Erlichman C,Hidalgo M,Boni JP,et al.Phase I study of EKB-569,an irreversible inhibitor of the epidermal growth factor re-ceptor,in patients with advanced solid tumors[J].J Clin Oncol,2006,24(15):2252-2260.
[11]Yoshimura N,Kudoh S,Kimura T,et al.EKB-569,a new irre-versible epidermal growth factor receptor tyrosine kinase inhibi-tor,with clinical activity in patients with non-small cell lungcancer with acquired resistance to gefitinib[J].Lung Cancer,2006,51(3):363-368.
[12]Wong KK,Fracasso PM,Bukowski RM,et al.HKI-272,an irre-versible pan ErbB receptor tyrosine kinase inhibitor:preliminaryphase 1 results in patients with solid tumors[J].J Clin Oncol,2006,24(18 suppl):3018-3020.
[13]Allen LF,Eiseman IA,Fry DW,et al.CI-1033,an irreversiblepan-ErbB receptor inhibitor and its potential application for thetreatment of breast cancer[J].Semin Oncol,2003,30(suppl16):65-78.
[14]Calvo E,Tolcher AW,Hammond LA,et al.Administration ofCI-1033,anirreversible pan-ErbB tyrosine kinase inhibitor,isfeasible on a 7-day on,7-day off schedule:Aphase I pharma-cokinetic and food effect study[J].Clin Cancer Res,2004,10(21):7112-7120.
[15]Nemunaitis J,Eiseman I,Cunningham C,et al.Phase 1 clinicaland pharmacokinetics evaluation of oral CI-1033 in patients withrefractory cancer[J].Clin Cancer Res,2005,11(10):3846-3853.
[16]Gieseg MA,de Bock C,Ferguson LR,et al.Evidence for epider-mal growth factor receptor-enhanced chemosensitivity in combi-nations of cisplatin and the newirreversible tyrosine kinase inhib-itor CI-1033[J].Anticancer Drugs,2001,12(8):683-690.
[17]Garland LL,Hidalgo M,Mendelson DS,et al.A phase I clinicaland pharmacokinetic study of oral CI-1033 in combination withdocetaxel in patients with advanced solid tumors[J].Clin CancRes,2006,12(14):4274-4282.
[18]Sandler A,Gray R,perry MC,et al.Paclitaxel-carboplatin aloneor with bevacizumab for non-small-cell lung cancer[J].NEn-gl J Med,2006,355(24):2542-2550.
[19]Herbst RS,Johnson DH,Mininberg E,et al.Phase I/II trial eval-uating the anti-vascular endothelial growth factor monoclonal an-tibody bevacizumab in combination with the HER-1/epidermalgrowth factor receptor tyrosine kinase inhibitor erlotinib for pa-tients with recurrent non-small-cell lung cancer[J].J ClinOncol,2005,23(11):2544-2555.
[20]Holden SN,Eckhardt SG,Basser R,et al.Clinical evaluation ofZD6474,an orally active inhibitor of VEGF and EGF receptorsignaling,in patients with solid,malignant tumors[J].Ann On-col,2005,16(8):1391-1397.
【关闭】
